Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Therapy in Wet AMD
NCT00805649Phase 4Completed
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Jan 2006
- Primary completion
- Jun 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in exudative macular degeneration (2 arms), sponsored by Universitätsklinikum Frankfurt. Primary endpoints: Best Corrected Visual Acuity and Central Macular Thickness. Started Jan 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00805649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805649.